Osaic Holdings’s Gain Therapeutics GANX Stock Holding History

Osaic Holdings’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.06K	Buy	+2,000	New	+$3.69K	﹤0.01%	7029
2024 Q1	–	Sell	-10,000	Closed	-$32.6K	–	7272
2023 Q4	$32.6K	Hold	10,000	–	–	﹤0.01%	5183
2023 Q3	$32.8K	Hold	10,000	–	–	﹤0.01%	5268
2023 Q2	$44.8K	Hold	10,000	–	–	﹤0.01%	5009
2023 Q1	$48.2K	Hold	10,000	–	–	﹤0.01%	4976
2022 Q4	$31K	Hold	10,000	–	–	﹤0.01%	5272
2022 Q3	$33K	Sell	10,000 -100	-1%	-$376	﹤0.01%	5234
2022 Q2	$36K	Buy	10,100 +50	+0.5%	+$172	﹤0.01%	5192
2022 Q1	$41K	Hold	10,050	–	–	﹤0.01%	5233
2021 Q4	$54K	Buy	+10,050	New	+$69.3K	﹤0.01%	5087

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Osaic Holdings's GANX Position: Q2 2026 in Review

Osaic Holdings opened a new position in Gain Therapeutics (GANX) in Q2 2026: 2,000 shares worth $4.06K. The stake represents ﹤0.01% of the portfolio and ranks #7029 among its holdings. This is a return to the name: Osaic Holdings previously reported a position in GANX as recently as Q4 2023.

Osaic Holdings first reported a position in GANX in Q4 2021 and has held it in 10 quarters since. The position peaked at $54K in Q4 2021. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Osaic Holdings held 2,000 shares of Gain Therapeutics worth $4.06K as of Q2 2026.
Gain Therapeutics was a new Osaic Holdings position in Q2 2026.
Gain Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7029 holding.
Osaic Holdings first reported a position in Gain Therapeutics in Q4 2021 and has held it in 10 quarters since.
Osaic Holdings's Gain Therapeutics position peaked at $54K in Q4 2021.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.